Comparative Pharmacology
Head-to-head clinical analysis: ELIPHOS versus GAVISCON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELIPHOS versus GAVISCON.
ELIPHOS vs GAVISCON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ELIPHOS is a phosphate binder that works by binding dietary phosphate in the gastrointestinal tract, forming non-absorbable complexes that are excreted in the feces, thereby reducing serum phosphate levels.
Gaviscon forms a protective alginate raft on top of gastric contents, providing a physical barrier that prevents reflux of gastric acid into the esophagus. The alginate reacts with gastric acid to form a gel-like foam that floats on the stomach contents. Gaviscon also contains antacids (calcium carbonate and sodium bicarbonate) that neutralize gastric acid.
10 mg orally once daily, with or without food.
10-20 mL orally after meals and at bedtime, maximum 80 mL/day
None Documented
None Documented
Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged in renal impairment.
Not applicable; Gaviscon acts locally in the stomach without systemic absorption of active ingredients. The alginate raft persists for 2-4 hours post-dose.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; approximately 10% is metabolized.
Primarily fecal as insoluble alginate rafts; minimal renal elimination (<1%) as absorbed components (sodium, potassium, calcium) excreted in urine.
Category C
Category C
Antacid
Antacid